Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Good day, and welcome to the ARS Pharmaceuticals Third Quarter ...

Ars Pharmaceuticals, Inc. ( (SPRY)) has released its Q3 earnings. Here is a breakdown of the information Ars Pharmaceuticals, Inc. presented to its investors. ARS Pharmaceuticals, Inc., a ...

Revenue: Total revenue was $2.1 million for the quarter ended September 30, 2024, comprised of $0.6 million in net product ...

ALK and ARS Pharmaceuticals sign a deal giving ALK global rights to Neffy nasal spray outside key regions, targeting peak ...

ARS Pharmaceuticals (SPRY) announced a licensing agreement with ALK-Abello A/S (AKBLF), that provides ALK exclusive rights to ...

ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.16 per share a year ago. These ...

Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025Exclusive ...

In a report released on November 11, Roanna Ruiz from Leerink Partners maintained a Buy rating on ARS Pharmaceuticals (SPRY – Research Report). The company’s shares closed yesterday at $16.61.

Cantor Fitzgerald has recently initiated ARS Pharmaceuticals Inc (SPRY) stock to Overweight rating, as announced on August 20, 2024, according to Finviz. Earlier, on August 13, 2024, Raymond James had ...

Although ARS Pharmaceuticals’ approval for its epinephrine nasal spray came later than expected, the company ultimately received a thumbs up from the FDA in August and is now moving fast to expand ...

Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.

ALK, a global specialty pharmaceutical company focused on allergy and allergic asthma, announced that it has entered into a strategic license agreement with US-based ARS Pharmaceuticals, Inc. (ARS ...